AXA IM Prime Impact Master Fund I SCA SICAV-RAIF 13D and 13G filings for Revelation Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-12 10:19 am Sale | 2023-12-31 | 13G | Revelation Biosciences, Inc. REVB | AXA IM Prime Impact Master Fund I SCA SICAV-RAIF | 3,498 0.900% | -583 (-14.29%) | Filing |
| 2023-02-14 12:39 pm Purchase | 2022-12-31 | 13G | Revelation Biosciences, Inc. REVB | AXA IM Prime Impact Master Fund I SCA SICAV-RAIF | 4,081 8.320% | 4,081 (New Position) | Filing |